

National HCL Update

Funding:

- **2026/27 funding:** The national funding available for ICBs over 2026/27 is ~£107m and indicative allocations will be shared with ICBs from Q1. Funding will remain SDF meaning ringfenced to support the continued roll out of HCL.

Data/activity update:

- **Q4 2025/26 activity** was shared with ICBs via Regions and Trusts along with useful info from NDA audit team inc. key dates. HCL tech Dashboard [Microsoft Power BI](#) – will be updated in due course to reflect 2025/26 full year's data

HIN Update

- All 11 Health Innovation Networks participating in the programme have been onboarded and attended prelaunch meetings with NHSE regional and central teams. Lead HIN has launched quarterly learning webinars for systems from May; set up a community of practice; and undertaken a revision of the HIN HCL workforce demand and capacity planning tool which is due to be launched soon. [The National Hybrid Closed Loop and Type 1 Diabetes Outpatient Transformation Programme - The Health Innovation Network](#)

HCL Pregnancy Advisory Group update

- Feedback on **NICE updated guidance** - [NICE issues new guidance on 'artificial pancreas' technology for pregnant women with type 1 diabetes | NICE](#) by the group especially using good outcome data seen by the use of pregnancy specific HCL usage
- Work on a **DAFNE module for HCPs** and a **DSM competency framework for diabetes specialist midwives** is underway and once complete will be referenced in the **Saving Babies Lives Care Bundle's** new version late summer

Evaluation

- **Paediatric HCL Evaluation** is led by the RCPCH and work continues. Plans for procurement of **Adults HCL Evaluation** continue.

Horizon scanning for new developments, NHS supply chain framework and related topics continues via the National team including options beyond the 5-year strategy

All tech

Focus on:

T1 HCL

T2 CGM

i

Home

NHS England



Selected data as at end of 2025/26 Q4

England

Percentage of people with Type 1 diabetes using Hybrid Closed Loop (HCL)



Age

Deprivation

Ethnicity


Sex

Time since diagnosis

Timeseries

Against other demographics

Change over time





0-18-year-olds: Hybrid Closed Loop (HCL) in those with type 1 diabetes

As at end of 2023/24
(baseline)





As at end of 2025/26
(provisional)

England
level 36%



England
level 76%





19–25-year-olds: Hybrid Closed Loop (HCL) in those with type 1 diabetes

As at end of 2023/24
(baseline)





As at end of 2025/26
(provisional)

England
level 8%




England
level 23%




ICB variation

0-18-year-olds: Hybrid Closed Loop (HCL) in those with type 1 diabetes as at end of 2025/26 (provisional data)




ICB variation

19-25-year-olds: Hybrid Closed Loop (HCL) in those with type 1 diabetes as at end of 2025/26 (provisional data)




Inequalities - Deprivation

Hybrid Closed Loop (HCL) in those with type 1 diabetes as at end of 2025/26
(provisional data)



Inequalities - Ethnicity

Hybrid Closed Loop (HCL) in those with type 1 diabetes as at end of 2025/26
(provisional data)



NHS rollout of artificial pancreas narrows inequality in diabetes care



Dr Clare Hambling, National Clinical Director for diabetes and obesity, said: “It is fantastic to see that the world-first rollout of this ground-breaking technology is already transforming the lives of tens of thousands of children and young people living with type 1 diabetes on the NHS.

“These revolutionary devices have represented a real step-change in care for so many families and this progress is testament to the dedication of our paediatric diabetes teams across the country to ensure as many young people who need them have been able to access them as quickly as possible, no matter where they live.”